Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ-PET, neurodegeneration, and cognition.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chatterjee Pratishtha, Vermunt Lisa, Gordon Brian A, Pedrini Steve, Boonkamp Lynn, Armstrong Nicola J, Xiong Chengjie, Singh Abhay K, Li Yan, Sohrabi Hamid R, Taddei Kevin, Molloy Mark, Benzinger Tammie L S, Morris John C, Karch Celeste, Berman Sarah, Chhatwal Jasmeer, Cruchaga Carlos, Graff-Radford Neill R, Day Gregory S, Farlow Martin, Fox Nick, Goate Alison, Hassenstab Jason, Lee Jae-Hong, Levin Johannes, McDade Eric, Mori Hiroshi, Perrin Richard, Sanchez-Valle Raquel, Schofield Peter R, Levey Allan, Jucker Mathias, Masters Colin L, Fagan Anne M, Bateman Randall J, Martins Ralph N, Teunissen Charlotte, Dominantly Inherited Alzheimer Network
Аннотация
METHODS: We evaluated plasma, serum, and cerebrospinal fluid (CSF) GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease.
RESULTS: Plasma GFAP elevations appear a decade before expected symptom onset, after amyloid beta (Aβ) accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished Aβ-positive from Aβ-negative ADAD participants and showed a stronger relationship with Aβ load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP.
CONCLUSION: Our findings support a role for plasma GFAP as a clinical biomarker of Aβ-related astrocyte reactivity that is associated with cognitive decline and neurodegeneration.
HIGHLIGHTS: Plasma glial fibrillary acidic protein (GFAP) elevations appear a decade before expected symptom onset in autosomal dominant Alzheimer's disease (ADAD). Plasma GFAP was associated to amyloid positivity in asymptomatic ADAD. Plasma GFAP increased with clinical severity and predicted disease progression. Plasma and serum GFAP carried similar information in ADAD, while cerebrospinal fluid GFAP did not.